§2.1.2 · Botanicals › Unclassified

1cP-LSD

1-Cyclopropionyl-d-lysergic acid diethylamide

Also known as Curie

Acute: Moderate riskDependency: Moderate risk

Images

Quick reference

Routes

Oral

Form

Blotter

Shulgin rating

++*

Duration

Onset

40 Minutes

Total duration

8 Hours

Experience

Primary effects

A potent lysergamide, considered a prodrug to LSD. May be slightly stronger than 1P-LSD at equivalent doses.
Induces strong open and closed eye visuals, including geometric patterns, drifting colors, and subtle movement in objects and walls.
Enhances physical sensations and tactile perception, depending on focus.

Peak character

Characterized by a 'rounded, vibrant, intelligent' feeling with clear, dirigible thoughts, allowing navigation of consciousness.
A subjectively strong and pleasing state of mind, featuring a robust psychedelic aura with periods of deep immersion.
A clearheaded and controllable experience, with ability to drift between analytical thinking and psychedelic absorption.

Negatives / side effects

Can be more intense than other lysergamides at comparable doses, be cautious with dosage.
Mental acuity may be impaired even at moderate doses, affecting complex tasks like strategy games.

Aftereffects / comedown

Visuals and headspace diminish relatively quickly after the peak, leading to a gentle comedown.
Lingering emotional sensitivity and altered perception of taste can persist for a few hours post-peak.
Can leave users feeling mentally fatigued the following day, even after sleep.

Reference dosage

Reference ranges from third-party harm-reduction databases. Individual response varies enormously — start lower than you think.

Any route

light	25ug+
common	50ug+
strong	100ug+

Reagent testing

Recommended reagents

Ehrlich Hofmann

Expected reactions

Ehrlich	Purple/violet
Hofmann	Blue → purple

Adulterant detection: Same profile as 1P-LSD. Absence of Ehrlich reaction indicates no indole — high risk of NBOMe substitution.

Prodrug of LSD; reagent profile identical to other lysergamides.

Source

Reference fields and narrative for 1cP-LSD extracted from The Drug Users Bible by Dominic Milton Trott (MxZero Publishing, 2022).

drugusersbible.com

Harm reduction notice

This platform provides educational and harm-reduction information adapted from public reference material. It does not endorse, encourage, or facilitate drug use. It is not medical advice. If you or someone near you may be in a medical emergency, contact local emergency services immediately.